Scinai Immunotherapeutics Ltd. ADR (SCNI)
NASDAQ: SCNIHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
Pre-market: 1.18 -2.48%
SCNI stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.64M
- P/E (TTM)
- 0.04
- EPS (TTM)
- $28.07
- Dividend yield
- None
- 52-week range
- 1.06 – 15.65
- Day range
- 1.06 – 1.23
- Volume / Avg
- 89.30K / 1.10M
- Beta
- —
- Shares outstanding
- 1.35M
52-week range
SCNI stock today
Scinai Immunotherapeutics (SCNI) closed at $1.21 on Oct 8, up 7.08% (+$0.08), versus the S&P 500's 0.47% decline. Trading was light, with 89.30K shares changing hands, about 8% of the average daily volume. Shares are 92.3% below their 52-week high of $15.65 and 14.2% above the 52-week low of $1.06, near the bottom of the past year's range.
Scinai Immunotherapeutics trades at 0.0x its trailing twelve-month earnings per share of $28.07.
Summary generated from market data by MetaCap's automated system. Methodology
About Scinai Immunotherapeutics
Company profileScinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's syndrome, and toxic epidermal necrolysis. The company also offers contract development and manufacturing organization services, such as analytical method development, process development, and cGMP manufacturing of clinical-stage materials to early-stage biotechnology companies.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Amir Reichman M.B.A., M.Sc.
- Headquarters
- Jerusalem
- Employees
- 45
- IPO year
- 2015
- Website
- scinai.com
Scinai Immunotherapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CRISCuris Inc. | 0.7094 | -3.69% | $1.72M | vs SCNI |
| HLSQTessera Defense and Homeland Security Inc. | 0.2915 | -5.72% | $2.63M | vs SCNI |
| VIVSVivoSim Labs Inc. | 0.1772 | -7.47% | $2.94M | vs SCNI |
| SLXNSilexion Therapeutics Corp | 0.2349 | -7.37% | $3.40M | vs SCNI |
| CLDICalidi Biotherapeutics Inc. | 1.04 | +2.97% | $3.82M | vs SCNI |
| PMCBPharmaCyte Biotech Inc. | 0.3974 | -2.02% | $4.27M | vs SCNI |
| LIMNLiminatus Pharma Inc. Class A | 3.69 | -4.65% | $4.96M | vs SCNI |
| CELZCreative Medical Technology Holdings Inc. | 0.8604 | -2.45% | $6.53M | vs SCNI |
Indexes, lists and sector
Scinai Immunotherapeutics stock FAQ
What is Scinai Immunotherapeutics's stock price today?
SCNI last traded at $1.21 as of Oct 8, 4:00 PM EDT, up 7.08% on the day. Prices are delayed at least 15 minutes.
What is SCNI's P/E ratio?
SCNI trades at a trailing P/E ratio of 0.04.
Who is Scinai Immunotherapeutics's CEO?
Mr. Amir Reichman M.B.A., M.Sc. is the chief executive officer of Scinai Immunotherapeutics Ltd. ADR, which has about 45 employees.
What is the SCNI 52-week high?
The 52-week high for SCNI is $15.65 and the 52-week low is $1.06. The stock is currently 92.3% below its high.